

# A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

<b>Submission date</b>	<b>Recruitment status</b>	<input type="checkbox"/> Prospectively registered
19/08/2002	No longer recruiting	<input type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
19/08/2002	Completed	<input type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
11/01/2019	Cancer	<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr --

### Contact details

UKCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

### Protocol serial number

LK/FIL

## Study information

### Scientific Title

A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

**Study objectives**

Not provided at time of registration

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Leukaemia (acute), Leukaemia (chronic)

**Interventions**

1. Arm A: Patients receive standard non-filtered, non-leukocyte-depleted blood products
2. Arm B: Patients receive Pall filtered blood or platelet donations

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Leukocyte-Depleted Red Cell and Platelet Donations

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

01/04/1992

## Eligibility

**Key inclusion criteria**

1. Patients with acute leukaemia, chronic myeloid leukaemia, severe aplastic anaemia or high grade lymphoma
2. Patients already known to have Human Leukocyte Antigens (HLA) antibodies or recurrent febrile transfusion reactions are ineligible

3. Any age
4. Fit to undergo the treatments as defined in protocol

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/1990

**Date of final enrolment**

01/04/1992

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

## Sponsor information

**Organisation**

Pall Biomedical Ltd (UK)

**ROR**

<https://ror.org/04hw9y579>

# Funder(s)

## Funder type

Industry

## Funder Name

Pall Biomedical Ltd (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration